

Genetic Selection for Enhanced Folding *In Vivo* Targets the Cys14-Cys38 Disulfide Bond in Bovine Pancreatic Trypsin Inhibitor

Linda Foit,* Antje Mueller-Schickert,* Bharath S. Mamathambika, Stefan Gleiter, Caitlyn L. Klaska, Guoping Ren, and James C.A. Bardwell

Abstract

The periplasm provides a strongly oxidizing environment; however, periplasmic expression of proteins with disulfide bonds is often inefficient. Here, we used two different tripartite fusion systems to perform *in vivo* selections for mutants of the model protein bovine pancreatic trypsin inhibitor (BPTI) with the aim of enhancing its expression in *Escherichia coli*. This trypsin inhibitor contains three disulfides that contribute to its extreme stability and protease resistance. The mutants we isolated for increased expression appear to act by eliminating or destabilizing the Cys14-Cys38 disulfide in BPTI. In doing so, they are expected to reduce or eliminate kinetic traps that exist within the well characterized *in vitro* folding pathway of BPTI. These results suggest that elimination or destabilization of a disulfide bond whose formation is problematic *in vitro* can enhance *in vivo* protein folding. The use of these *in vivo* selections may prove a valuable way to identify and eliminate disulfides and other rate-limiting steps in the folding of proteins, including those proteins whose *in vitro* folding pathways are unknown. *Antioxid. Redox Signal.* 14, 973–984.

Introduction

DISULFIDE BONDS are critical posttranslational modifications that regulate the folding and stability of proteins. The activities of many extracellular and pharmaceutically relevant proteins such as insulin and the tissue plasminogen activator rely on the formation of their correct disulfide bond pattern (22). *Escherichia coli* is a preferred host for heterologous protein expression due to its simple and inexpensive cultivation, ease of genetic manipulation, and the comprehensive understanding of its genetics (40). Because of its ability to form disulfide bonds, the oxidizing environment of the bacterial periplasm in particular is often the compartment of choice for the expression of disulfide bond-containing proteins (3).

Frustratingly, despite the extremely high native-state stability of proteins with multiple disulfide bonds (34), heterologous proteins with complex disulfide bond patterns often express very poorly in *E. coli* (32). One example is the bovine pancreatic trypsin inhibitor (BPTI) (31), which in its mature form contains three nonconsecutive disulfide bonds involving

all of its six cysteines. Fully oxidized, native BPTI has a melting temperature of over 100°C (36). However, the protein folds poorly in bacteria, resulting in very low expression yields (31). The *in vitro* folding pathway of BPTI is probably the most intensively studied of all proteins and is dominated by the formation and isomerization of its disulfide bonds (1, 16, 45). Conversely, much less is known about the *in vivo* folding of BPTI, especially in heterologous systems (31–33). It is still not clear whether the folding challenges BPTI faces *in vitro* are also responsible for its relatively low expression in heterologous systems compared to that of other proteins (31).

In this study, we utilized two independent genetic systems to select for BPTI variants that exhibit improved expression and folding properties in the *E. coli* periplasm. The nature of the BPTI variants obtained supports the theory that destabilization or elimination of the native disulfide bond Cys14-Cys38 allows for a more productive route of folding toward the native state *in vivo*. The use of *in vivo* selections may therefore prove to be a valuable way to identify and circumvent critical rate-limiting steps in the *in vivo* folding of proteins, including those proteins whose *in vitro* folding pathways are unknown.

Department of Molecular, Cellular and Developmental Biology, Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan.

*These two authors contributed equally to this work.

Materials and Methods

Cloning of phages for the protein stability increased by directed evolution system

fd phage derivatives were grown on XL1-Blue *E. coli* cells (Stratagene, La Jolla, CA). For cloning and sequencing of phage DNA, the replicative form was prepared using a Qiagen Miniprep Kit (Qiagen, La Jolla, CA). To construct tripartite fusions within the g3p protein of fd, a derivative of fd phage called fdP213 was used. This variant carries the g3p protein stabilizing mutations T13I, T101I, Q129H, D209Y, and P213G (29). The gene for BPTI was amplified from pTI103 plasmid (15) using the primers 5'-TAATTAGGGCCCCG CCTGACTTCTGC-3' and 5'-GCTAATAGGGCCCCACCAC AGGTCCTCATGCA-3'. These primers introduced *Apa*I sites at the 5' and 3' ends of the gene for mature portion of BPTI, enabling its insertion into the *Apa*I site that had been previously engineered into the g3p gene of fd phage by Krebber *et al.* (25). This allowed the in-frame cloning of BPTI into the g3p gene with no change in the amino acid sequence of BPTI, resulting in the phage PHSG7. It also placed BPTI between the N- and the C-terminal domains of the g3p protein. Inverted inserts were selected against because they created stop codons in g3p, preventing phage infectivity. The resulting fusion protein is referred to as "g3p'-BPTI WT'-g3p."

Directed evolution of BPTI in the phage system

Mutagenesis of the BPTI gene was performed according to the GeneMorph II EZClone domain mutagenesis kit (Stratagene) with some minor modifications. Briefly, the BPTI sequence was amplified from pHSG7 DNA in an error-prone polymerase chain reaction (PCR) using the Mutazyme II enzyme mix and primers 5'-CTGTCAATGCTCCGTCGGG GGCC-3' and 5'-GTACCAGAAGCCATGGCCGGCTG-3', which annealed up- and downstream of the BPTI gene. The PCR was performed as recommended by Stratagene, except that the annealing temperature was 55°C and the elongation time was 1 min. The resulting pool of mutagenized BPTI genes was then used to perform a second, nonmutagenic PCR on pHSG7 DNA, according to the GeneMorph II protocol, to complete the synthesis of the fd phage. After digestion with *Dpn*I (New England Biolabs, Beverly, MA), the remaining PCR product was precipitated. The resuspended DNA pellet was transformed into XL1-Blue cells, and the cultures were grown in LB for 14 h at 37°C. This simple outgrowth served as a growth competition selection that allowed the most infectious phage to outgrow less infectious phages in the culture. This protocol was designed to enable the selection of mutations within the BPTI gene that conferred a growth advantage to the g3p-BPTI tripartite fusion containing fd phage. Subsequently, the cultures were pelleted and the phage containing supernatant was plated using 0.7% top agar LB in different dilutions. Plaques larger than those of the unmutagenized pHSG7 phage (which generated tiny, almost invisible plaques) were picked and used to re-infect 10 ml of an overnight culture of XL1-Blue cells. These cells were again grown for 14 h to grow up the large plaque phage clones. After harvesting, the phage titer [plaque forming units (pfu)/ml] was determined, and the sequence of the BPTI gene determined from the isolated replicative form of the phage.

Directed evolution of BPTI in the β -lactamase system

To construct a tripartite fusion between BPTI WT and β -lactamase, the gene for BPTI was first PCR-amplified from pTI103 using primers 5'-CTGTCAATGCTCCGTCGGG GCC-3' and 5'-GTACCAGAAGCCATGGCCGGCTG-3' and then cloned into the *Pfo*I site within the β -lactamase gene in pBR322*link to obtain pBR322*link-BPTI. The resulting fusion protein is referred to as bla'-BPTI WT'-bla. The BPTI gene was then randomly mutagenized, and clones that showed an enhanced resistance to penicillin V (Pen V) or ampicillin were isolated, and the minimal inhibitory concentration (MIC) of antibiotic necessary to inhibit their growth was determined as previously described (13). Additional specific mutations in BPTI were generated using the QuikChange™ Site-Directed Mutagenesis Kit (Qiagen).

Determination of expression levels

Whole cell extracts were prepared as previously described (13).

For the separation of the soluble and insoluble fractions, mid-log-phase cells were pelleted (13,000 g, 4°C, 5 min) and adjusted to OD_{600 nm} = 7 in lysis buffer (10 mM Tris, 2 mM EDTA, 1 mg/ml lysozyme, and protease inhibitor). One hundred microliters of this mixture was subjected to 10 freeze-thaw cycles and the soluble and the insoluble fractions were separated by centrifugation (13,000 g, 4°C, 10 min). The supernatant after centrifugation was the soluble fraction. The pellet (insoluble fraction) was resuspended in a total volume of 100 μ l resuspension buffer (3.2 mM Na₂HPO₄, 0.5 mM KH₂PO₄, 1.3 mM KCl, 135 mM NaCl, 2 mM EDTA, and protease inhibitor, pH 7.4).

For the preparation of periplasmic extracts, a volume of mid-log-phase cells corresponding to OD_{600 nm} = 7 was pelleted (13,000 g, 4°C, 10 min) and resuspended in 70 μ l osmotic shock buffer (0.2 M Tris pH 8, 0.5 M sucrose, 1 mM EDTA). After incubation on ice for 30 min, the supernatant (periplasmic extract) and the pellet (cytoplasmatic fraction) were separated by centrifugation (13,000 g, 4°C, 10 min).

To obtain samples in which bla'-link-BPTI'-bla would still contain its signal sequence, mid-log phase cells expressing bla'-link-BPTI'-bla under arabinose control were induced with 2% arabinose. After 2 min, the cells were treated with 0.08% sodium azide, incubated for another 18 min, and whole cell extracts were prepared as described above. For the expression of BPTI in the absence of β -lactamase, BPTI was expressed from pET11a (New England Biolabs) under a T7 promoter. Protein production was induced with 5 μ M IPTG.

Protein samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis. Proteins were detected using a monoclonal rabbit antibody raised against TEM1- β -lactamase (Millipore, Billerica, MA) or reduced BPTI (generous gift from George Georgiou) as a primary and HRP-goat anti-rabbit IgG (Thermo Scientific, Waltham, MA) as a secondary antibody. Various dilutions of the protein samples for constructs containing WT BPTI and the BPTI variants were loaded on the gel. For each dilution, the ratio of band intensities for the mutant BPTI and WT BPTI was determined and averaged.

Results

To select for variants of BPTI that show enhanced expression and folding in the bacterial periplasm, we employed two independent tripartite fusion approaches that link the *in vivo* folding of BPTI to the activity of a reporter protein. The first approach was a modification of the protein stability increased by directed evolution (PROSIDE) technique (29); the second approach was the split β -lactamase system developed in our lab (13). In the PROSIDE approach, a guest protein is inserted between the N- and C-terminal domains of the g3p capsid protein of the fd phage (Fig. 1A). Both domains must remain covalently linked for g3p to be functional and confer phage infectivity. If the inserted protein is poorly folded or unstable, it becomes proteolytically sensitive. Degradation of the inserted protein will lead to a separation of the N- and C-terminal domains and a loss of infectivity. However, if the inserted guest protein folds well, the two domains of g3p remain covalently linked, and the phage carrying the fusion protein is infectious. This method therefore directly links the *in vitro* stability of the guest protein with phage infectivity. Improved folding efficiency of the guest protein in the periplasm should result in a higher infectivity of the phage, resulting in larger plaque sizes and increased phage titers.

In the β -lactamase system, the guest protein is inserted between the N- and C-terminal halves of TEM1- β -lactamase, a periplasmic enzyme that confers resistance to β -lactam antibiotics (13) (Fig. 1B). We used this technique previously to monitor the *in vivo* stability of a variety of different proteins and to identify variants with improved thermodynamic and kinetic stability by selecting for increased levels of antibiotic resistance (13). As in the PROSIDE system, poor folding of the guest protein makes it susceptible to proteolytic degradation, leading to a separation of the two halves of the reporter protein. Bacteria expressing such a construct are therefore sensitive to antibiotic stress. A well-folded guest protein, however, ensures that the fusion remains intact, thereby leading to high levels of antibiotic resistance.

Selecting for BPTI variants that lead to increased infectivity in the PROSIDE system

The phage system links the proteolytic stability of a guest protein to phage infectivity and therefore to the rate of phage amplification. Insertion of WT BPTI into the protein g3p of the fd phage (referred to as "g3p'-BPTI WT'-g3p") resulted in a dramatic decrease in phage titer (from $\sim 10^{11}$ pfu/ml for WT fd phage to $\sim 10^6$ pfu/ml for g3p'-BPTI WT'-g3p, Table 1). This result is consistent with the poor *in vivo* folding and expression of BPTI noted previously (33). We reasoned that by mutagenizing the BPTI portion of the fusion and selecting for variants that show improved phage growth, we should be able to identify mutants with improved *in vivo* expression and folding properties. About 22 independent mutagenesis reactions yielded a total of 42 phage variants that resulted in increased plaque sizes and higher phage titers. Sequence analysis revealed two classes of fd variants that improved phage growth. The first class consisted of 25 independent deletion variants in which all or nearly all of the BPTI encoding sequence was selectively removed from the g3p gene. These deletion variants all showed titers and plaque sizes comparable to the original WT phage (data not shown). The remaining 17 phage variants had acquired single or multiple mutations in the BPTI




FIG. 1. Directed evolution of proteins using the modified protein stability increased by directed evolution and the β -lactamase tripartite fusion systems. The test protein BPTI (shown in orange) is inserted into either the minor coat protein of the fd phage, g3p, (A) or β -lactamase (B), creating a tripartite fusion. (A) During phage replication in *Escherichia coli*, g3p is first synthesized as an integral membrane protein (not shown) before it is assembled into the phage coat (not shown). The N-terminal domain of g3p carries the recognition site for the bacterial receptors the phage binds to during infection, and the C-terminal domain anchors g3p into the phage coat. Therefore, both domains must remain covalently linked for g3p to be functional and maintain phage infectivity. (B) β -lactamase (bla) is a periplasmic enzyme that inactivates β -lactam antibiotics. The ability of the tripartite fusions to confer phage infectivity (A) or resistance to antibiotics (B) is strongly dependent on the *in vivo* stability of the guest protein that is inserted into the reporter protein. If the test protein is stable and folded properly, the two halves of the reporter protein remain covalently linked and confer activity (left). If the inserted protein is not properly folded or unstable, it is prone to degradation by periplasmic proteases (depicted as scissors) and is likely to be degraded (right). This leads to a separation of the N- and C-terminal fragments of g3p/ β -lactamase, resulting in a decreased phage titer/antibiotic resistance (13). BPTI, bovine pancreatic trypsin inhibitor. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com/ars).

sequence and showed increased plaque size and titer compared to g3p'-BPTI WT'-g3p (listed in Table 1).

For the two BPTI variants with single mutations (F33L and G12D), it is clear that the single mutation is sufficient for the enhanced growth phenotype. The vast majority of BPTI variants isolated, however, contained multiple amino acid substitutions, complicating interpretation. Many of the residues

TABLE 1. PHAGE TITERS FOR BOVINE PANCREATIC TRYPSIN INHIBITOR VARIANTS OBTAINED WITH THE PHAGE SYSTEM

<i>g3p'</i> -BPTI- <i>g3p</i> variant	Relative phage growth
WT fd phage	+++++
BPTI WT	+/-
<u>G12D</u>	+++
<u>F33L</u>	+++
<u>C14S</u> , C38S	+++++
C14R, C38Y, P2S, D3F	++++
C14Y, C38W, A40D	++++
C14Y, C38Y, R42S, K46M	++++
<u>Y35N</u> , A40S, K41N	+++
<u>R17G</u> , G37N	+++
<u>A16T</u> , I18N, S47N	+++
<u>A16N</u> , V34E	+++
I18S, A40S	+++
L6Q, R17S	+++
V34E, S47N	+++
F4L*, <u>A16T</u> , R39N	+++
F4L*, <u>K26N</u> , R39S	+++
P13S, <u>Y35G</u>	+++
<u>Y35N</u> , <u>G36D</u> , R42S, S47N	+++

Insertion of WT BPTI into the *g3p* encoding sequence of the phage decreased the phage titer from $\sim 10^{11}$ pfu/ml (+++++) to 10^6 pfu/ml (+/-). Titers varied significantly from experiment to experiment; values shown are the average of 3 experiments. +++ corresponds roughly to a phage titer of 10^{10} pfu/ml, +++ roughly to 10^9 pfu/ml. Residues in bold were found to be substituted in multiple independent mutagenesis reactions. In most of these cases, the chemical nature of the amino acid substitution was the same. Underlined are the BPTI exact amino acid substitutions that were previously found to selectively reduce the Cys14-Cys38 disulfide upon adding DTT *in vitro* (2, 18) and/or are known to destabilize this particular disulfide bond *in vitro* (17). Dotted underlined variants eliminate the Cys14-Cys38 disulfide bond completely. Variants that have been shown to decrease the accumulation of kinetic traps in the folding pathway of BPTI *in vitro* are marked with * (50).

BPTI, bovine pancreatic trypsin inhibitor; DTT, dithiothreitol; pfu, plaque forming unit; WT, wild-type.

substituted were isolated on multiple occasions; 12 of the 33 point mutations identified affected residues that were found to be altered in multiple, independent mutagenesis reactions (shown bold in Table 1). We reasoned that the more often a residue was independently replaced in different BPTI variants, the more likely that alteration of this residue is important for robust growth of the phage expressing the *g3p*-BPTI variant. Among the isolated BPTI variants, six residues (F4, R17, I18, V34, R39, and R42) were independently found to be mutated twice, four (A16, Y35, A40, and S47) were mutated three times, and two (C14 and C38) were mutated four times. It is striking that of the 15 BPTI variants with multiple amino acid substitutions, the four variants exhibiting the largest increase in phage titer all eradicate the Cys14-Cys38 disulfide by eliminating both of the involved cysteines. Remarkably, seven of the substitutions that do not affect the cysteines are exactly the same as substitutions that have previously been found to destabilize Cys14-Cys38 *in vitro* (underlined in Table 1) (17).

To confirm that these amino acid substitutions are, on their own, sufficient to increase phage titers compared to phage containing WT BPTI, we attempted to construct the individual mutations in the phage system by site-specific mutagenesis. However, the very strong growth disadvantage conferred

upon fd by *g3p* fusions containing WT BPTI and the resulting low titer greatly decreased the amount of DNA that could be isolated from the WT BPTI construct, making site-specific mutagenesis very difficult. When high yields of DNA were obtained, we observed that it was often the result of the spontaneous evolution of phage containing deletions or other mutations within BPTI. The underlying basis of this problem is unfortunately exactly the same as the basis of the genetic selection; namely, the coupling of the growth of the phage to the folding of the test protein.

Selecting for BPTI variants that lead to increased antibiotic resistance in the β -lactamase system

To circumvent the problem of low DNA levels and frequent excisions of the BPTI gene from the phage genome, we decided to establish growth conditions in which the folding of the inserted protein could be selectively uncoupled from the growth of strains containing the selectable marker. This was not possible for the *g3p* tripartite fusions because *g3p* is required for phage propagation and consequently phage DNA amplification. We therefore employed a second genetic selection system, the β -lactamase system. Here, the tripartite fusion is expressed from a bacterial plasmid that also encodes for an additional selectable marker, tetracycline resistance. Growing cells containing this plasmid in tetracycline allows for an easy amplification and manipulation of plasmid DNA without any requirement for efficient folding of the tripartite β -lactamase protein. The β -lactamase system further provides a very reproducible readout for the relative level of antibiotic resistance conferred by different tripartite fusions (13).

The construction of a plasmid expressing a tripartite fusion between BPTI WT and β -lactamase (referred to as "bla'-BPTI WT-bla") and the determination of the resulting level of antibiotic resistance is described in Materials and Methods. Antibiotic resistance is given as the MIC that prevents cell growth. The level of resistance caused by a given BPTI mutant is normalized to the level of resistance conferred by bla'-BPTI WT-bla. The insertion of BPTI into β -lactamase resulted in a massive drop in antibiotic resistance compared to cells expressing WT β -lactamase, similar to the drop in phage infectivity that accompanied the insertion of BPTI into *g3p* (Fig. 2). As with the phage selection, we randomly mutagenized the BPTI portion of the tripartite fusion gene; however, in this case, we selected for increased antibiotic resistance to identify BPTI variants that show enhanced protein levels and folding in the periplasm. Using this approach, we isolated 13 point variants and 1 triple variant (P13S C14Y G28R) that showed increased MIC values compared to cells expressing bla'-BPTI WT-bla (Table 2). We also constructed point variants P13S and G28R in the BPTI WT background by site-specific mutagenesis, and they also showed increased levels of antibiotic resistance. Variants isolated with the β -lactamase system that eliminate or destabilize the Cys14-Cys38 disulfide bond are underlined in Table 2.

For the two point mutations that led to the largest increase in MIC, BPTI G28W and K26M, we also tested the steady-state protein levels in the periplasm. These measurements were made both for BPTI when it was part of the tripartite fusion, as well as the isolated BPTI protein expressed on its own in the absence of β -lactamase. In both these contexts the protein levels of BPTI G28W and K26M in whole cell extracts were




FIG. 2. Insertion of BPTI into β -lactamase leads to a massive drop in antibiotic resistance compared to cells expressing the unmodified enzyme. Mid-log phase cells of *E. coli* MG1655 $\Delta ampC$ expressing TEM1- β -lactamase (bla WT) or TEM1- β -lactamase fused with WT BPTI (bla'-BPTI WT-'bla), respectively, were normalized to $OD_{600\text{ nm}} = 1$. Serial dilutions of cultures from 10^0 to 10^{-5} were spotted on LB plates containing different concentrations of ampicillin. After 18 h of incubation at 37°C , growth or no growth for each dilution for each ampicillin concentration was determined. WT, wild-type.

significantly increased compared to the corresponding WT constructs (2.5 ± 0.2 -fold for BPTI G28W and 2.8 ± 0.3 -fold for K26M in the fusion context, compared to the protein level of bla-BPTI WT-bla; 1.5 ± 0.1 -fold for BPTI G28W and 1.7 ± 0.2 -fold for K26M in the isolated protein in the absence of the fusion, compared to the protein level of WT BPTI itself. This

suggests that the β -lactamase system works well for the selection of protein variants with increased expression in *E. coli*.

Destabilization of Cys14-Cys38 in vitro correlates with increased levels of antibiotic resistance in the β -lactamase system in vivo

Because disulfide bonds act to stabilize proteins, we were initially surprised that the elimination or destabilization of Cys14-Cys38 in BPTI was actually reflected in improved phenotypes in the phage system. We were therefore interested in whether the degree of destabilization of the Cys14-Cys38 disulfide as determined *in vitro* would correlate with increased protein stability *in vivo* as reflected by improved phenotypes in the tripartite fusion systems. In contrast to the phage system, which was characterized by a rather high propensity for recombination events that lead to the elimination of the protein inserted into g3p and phage titers that varied significantly from experiment to experiment, the β -lactamase system is genetically very stable and has been shown to provide a very reproducible phenotype for a variety of insert proteins (13). We introduced four of the amino acid substitutions that were obtained in the phage selection as point mutations into the bla'-BPTI WT-'bla background, and one mutant, Y35L, that was derived from the literature (17). All five BPTI variants are known to destabilize this disulfide bond *in vitro* (17). Remarkably, the extent of thermodynamic destabilization of Cys14-C38 caused by a given point mutation *in vitro* correlated well with the level of antibiotic resistance in the β -lactamase system (Fig. 3). Consistent with these

TABLE 2. MINIMAL INHIBITORY CONCENTRATION VALUES FOR BOVINE PANCREATIC TRYPSIN INHIBITOR VARIANTS OBTAINED WITH THE β -LACTAMASE SYSTEM

<i>BPTI variants obtained in the selection</i>		<i>BPTI variants constructed via site-directed mutagenesis</i>	
<i>bla'-BPTI-'bla</i>	<i>MIC $\pm$ SD</i>	<i>bla'-BPTI-'bla</i>	<i>MIC $\pm$ SD</i>
bla WT	2.07 ± 0.07	<u>A16T</u>	0.98 ± 0.02
BPTI WT	1.00 ± 0.00	<u>F33L</u>	0.94 ± 0.06
N24H	1.07 ± 0.06	<u>Y35N</u>	1.01 ± 0.08
P13S^a	1.10 ± 0.02	<u>Y35L</u>	1.07 ± 0.01
<u>I18L</u>	1.10 ± 0.02	<u>N24A</u>	1.08 ± 0.08
<u>I19F</u>	1.17 ± 0.01	<u>Y35G</u>	1.12 ± 0.04
<u>Y10N</u>	1.23 ± 0.02	<u>Y23L</u>	1.18 ± 0.01
<u>Q31K</u>	1.23 ± 0.01		
<u>A25V</u>	1.23 ± 0.05	[14-38]	0.13 ± 0.02
<u>Q31R</u>	1.25 ± 0.01	[30-51]	0.90 ± 0.03
<u>P13L</u>	1.36 ± 0.04	[5-55]	1.46 ± 0.03
<u>G28R^a</u>	1.37 ± 0.01		
<u>C14W</u>	1.43 ± 0.06	[5-55] [14-38] ^b	0.74 ± 0.02
<u>N24K</u>	1.50 ± 0.09	[14-38] [30-51] ^b	1.10 ± 0.03
<u>K26M</u>	1.88 ± 0.09	[5-55] [30-51] ^b	1.70 ± 0.06
<u>G28W</u>	1.91 ± 0.10		
<u>P13S C14Y G28R^a</u>	1.35 ± 0.08		

The relative level of antibiotic resistance of cells expressing different bla'-BPTI-'bla variants is given as the minimal inhibitory concentration (MIC) that prevents cell growth (see the Materials and Methods section). Residues in bold were substituted more than once in independent mutagenesis reactions. In most of these cases, the chemical nature of the amino acid substitution was the same. Residues underlined were identified in a screen for DTT-sensitive mutants as single point mutations or are known to destabilize the Cys14-Cys38 disulfide *in vitro* (2, 17, 50). The dotted underlined variants prevent formation of Cys14-Cys38.

^aP13S and G28R were selected as part of a triple mutant (P13S C14Y G28R) and subsequently constructed as single point mutations *via* site-directed mutagenesis.

^bRelative protein levels of [5-55] [14-38], [14-38] [30-51], and [5-55] [30-51] in the β -lactamase system were 0.9 ± 0.1 , 1.2 ± 0.2 , and 1.6 ± 0.1 , respectively.

SD, standard deviation.




FIG. 3. Increased destabilization of the Cys14-Cys38 disulfide bond *in vitro* correlates with increased antibiotic resistance in the β -lactamase system *in vivo*. Different variants of BPTI were inserted into β -lactamase *via* flexible linkers. The level of antibiotic resistance for cells expressing the corresponding fusion constructs was determined as described in the Materials and Methods section. BPTI variants containing single amino acid substitutions that were either identified in the phage selection (A16T, F33L, Y35N, and Y35G) or obtained from the literature (Y35L) are indicated with filled diamonds (17). The relative level of antibiotic resistance (indicated by MIC) compared to a tripartite fusion containing BPTI WT *in vivo* is plotted against the thermodynamic destabilization $\Delta\Delta G$ of the Cys14-Cys38 disulfide bond in the mutant proteins as determined *in vitro* ($\Delta\Delta G = RT \ln[C_{\text{eff}}(\text{WT})/C_{\text{eff}}(\text{mut})]$, where $C_{\text{eff}}(\text{WT})$ and $C_{\text{eff}}(\text{mut})$ are the effective concentrations of the Cys14-Cys38 disulfide bond in WT BPTI or the mutant proteins, respectively) (17). Stability values for a BPTI species in which the formation of Cys14-Cys38 was prevented by either carboxymethylation or carboxyamidomethylation were taken from Schwarz *et al.* (36) and plotted against the level of resistance conferred by bla'-BPTI C14S C38S-bla. These latter variants are proteins with chemical side chain modifications rather than mutations, and their thermodynamic destabilization values were determined using a different methodology. Therefore, their absolute values may not be precisely comparable to the single amino acid substitutions; they are shown as open diamonds. The R^2 value for the single point variants (filled diamonds) is 0.89, and the R^2 for the complete data set is 0.91. Data are expressed as mean values $\pm$ SD. MIC, minimal inhibitory concentration; SD, standard deviation.

findings, complete removal of the Cys14-Cys38 disulfide bond leads to an even higher MIC (Fig. 3, open diamonds). Importantly, the elimination of the Cys14-Cys38 disulfide bond increases the protein level of BPTI in *E. coli* both when it is part of the tripartite fusion as well as when BPTI is ex-

pressed on its own (1.6 ± 0.1 -fold increase in protein level relative to bla'-BPTI WT-bla in presence of β -lactamase and 2.3 ± 0.2 -fold increase in protein level relative to BPTI WT in absence of β -lactamase, respectively). These results fit nicely with a previous observation that the elimination of this disulfide by serine substitutions leads to a 7-fold increase in the expression level of BPTI in the *E. coli* periplasm (31).

The stabilities of single disulfide-bonded BPTI species in vitro correlate with the level of antibiotic resistance in the β -lactamase system in vivo

Because the β -lactamase system has been shown to be a good readout for the *in vivo* stability of a variety of proteins (13), we decided to use it to assess which of the different intermediates that accumulate in BPTI's folding pathway *in vitro* might be especially problematic for BPTI's folding *in vivo*. Traditionally, much information about the folding pathway of BPTI has been obtained by studying the properties of analogs of folding intermediates (11) in which particular pairs of cysteines were chemically blocked or replaced with other amino acids, especially serine (6). To create three BPTI variants that can only form a single native disulfide bond, we used site-directed mutagenesis to replace all but one cysteine pair with serines. We list the disulfide mutants we constructed and define our nomenclature in Table 3. Among the single disulfide-bonded species containing native disulfides, BPTI [5–55] has the most native-like conformation *in vitro*, whereas [14–38] has the least (26, 41). Introduction of [5–55] into the β -lactamase system resulted in the highest MIC, whereas introduction of the least structured and least stable species ([14–38]) resulted in the lowest MIC, suggesting that the latter intermediate does not form a stable conformation in the bacterial periplasm (Fig. 4A). These results indicate that, for single disulfide-bonded species of BPTI, the extent of native structure *in vitro* is correlated to the MIC *in vivo*. Consistently, the levels of antibiotic resistance for BPTI [5–55], [14–38], and [30–51] correlate very well with the contribution of the particular disulfide bond to the stability of the folded conformation, as reflected by the effective concentration of the disulfide bond in the native state (7, 23) (Fig. 4B). Interestingly, there is an inverse correlation between the MIC and the tendency of a disulfide to form in reduced BPTI: the higher the conformational preference for formation of a particular native disulfide in the reduced state, the lower the MIC of the BPTI variant that can only form this particular disulfide (Fig. 4C). An inverse correlation was also found between the MIC and the reactivity of the involved cysteines, with higher reactivities

TABLE 3. NOMENCLATURE FOR BOVINE PANCREATIC TRYPSIN INHIBITOR VARIANTS USED IN THIS STUDY

BPTI species	Alternative name	Contains disulfide bond(s)	Corresponds to BPTI variant in the β -lactamase system
[5–55]	–	Cys5-Cys55	C14S C30S C38S C51S
[14–38]	–	Cys14-Cys38	C5S C30S C51S C55S
[30–51]	–	Cys30-Cys51	C5S C14S C38S C55S
[5–55; 14–38]	–	Cys5-Cys55 and Cys14-Cys38	C30S C51S
[5–55; 30–51]	–	Cys5-Cys55 and Cys30-Cys51	C14S C38S
[14–38; 30–51]	–	Cys14-Cys38 and Cys30-Cys51	C5S C55S
[5–55; 14–38; 30–51]	Wild-type	Cys5-Cys55, Cys14-Cys38 and Cys30-Cys51	

CysX-CysY refers to a disulfide bond formed between cysteine residue X and cysteine residue Y. BPTI variants representing folding intermediates found *in vitro* were obtained by substituting cysteines not involved in disulfide bond formation with serines.




FIG. 4. In BPTI variants that can only form a single disulfide bond, the stability of the disulfide bond *in vitro* correlates with the level of antibiotic resistance in the β -lactamase system *in vivo*. (A) Three variants of BPTI representing single disulfide-bonded intermediates ([14-38], [30-51], or [5-55], respectively) were inserted into β -lactamase *via* flexible linkers. In all variants, the cysteines not involved in formation of the disulfide bond indicated were substituted with serines. Bla WT indicates WT β -lactamase without any insertions, and BPTI WT refers to the construct bla'-BPTI WT'-bla. The level of antibiotic resistance (indicated by MIC) for cells expressing the corresponding fusion constructs was determined as described in the Materials and Methods section and is normalized to cells expressing bla'-BPTI WT'-bla. (B) The "effective concentration" of two interacting groups in the native-like conformation can be used as an expression of the free energy of the intermolecular interaction (23). The higher the effective concentration, the larger is the contribution of the particular interaction to the stability of the folded formation. Values for the effective concentrations were taken from Creighton and Goldenberg (7). (C) In the reduced state, the kinetic effective concentration can be used to assess the extent to which two cysteines are brought into proximity to each other (9). Values for the effective concentration for the three disulfide bonds indicated were taken from Dadlez and Kim (9). Data are expressed as mean values $\pm$ SD.

resulting in lower MICs (data not shown) (9). Further, we observed that a single disulfide-bonded variant of BPTI, [5-55], which is substantially less stable than the native protein (43), exhibits a higher MIC than WT BPTI in the β -lactamase system (Table 2), and this is testimony to the severe folding problems WT BPTI faces in the periplasm of *E. coli*.




FIG. 5. The majority of BPTI [14-38] detected in whole cell extracts is periplasmic, but insoluble. Cell fractions were prepared from *E. coli* MG1655b $\Delta ampC$ cells expressing bla'-BPTI WT'-bla or bla'-BPTI [14-38]'-bla, respectively, as described in the Material and Methods section. The tripartite fusions were detected by Western blot using an anti- β -lactamase antibody. In cells treated with sodium azide, the Sec pathway is blocked and the export of the tripartite fusions prevented (NaN₃). Here, tripartite fusion proteins remain in the cytosol and retain their signal sequence, which is usually cleaved upon export in the periplasm. Tripartite fusions that were exported (as detected in the periplasmic extracts [PE], indicated with peri.) can therefore be distinguished from fusion proteins that were retained in the cytosol (as detected in the sample treated with NaN₃, indicated with cyto.) by their molecular weight. The blot shows that for both bla'-BPTI WT'-bla and bla'-BPTI [14-38]'-bla, all fusion protein detected in whole cell extracts (WC) is located in the periplasm. However, for bla'-BPTI [14-38]'-bla the amount of soluble protein is much lower than for bla'-BPTI WT'-bla (compare soluble [SO] and insoluble fractions [IS]).

Because the MIC is a measure of how many molecules are successfully exported, we wondered if the low MIC caused by bla'-BPTI [14-38]'-bla was the result of a preferred formation of this disulfide in the cytosol, preventing export. bla'-BPTI [14-38]'-bla showed a protein level in whole cell extracts that was substantially higher than expected from its MIC value (protein level was 1.1 ± 0.1 , MIC was only 0.13 ± 0.0 compared to bla'-BPTI WT'-bla). Subsequent analysis of soluble/insoluble and periplasmic/cytosolic fractions of cells expressing bla'-BPTI [14-38]'-bla indicated that the majority of the protein was periplasmic, but insoluble (Fig. 5). This result is in stark contrast to that obtained for the rest of the bla'-BPTI'-bla variants, which showed a very good correlation between level of antibiotic resistance and steady-state levels of the fusion proteins in whole cell extracts (Fig. 6). The latter observation is consistent with previous experiments using the β -lactamase system, which showed that the level of antibiotic resistance is a good measure for the relative level of the fusion protein in the periplasm (13). However, the actual amount of soluble, periplasmic bla'-BPTI [14-38]'-bla reflected the observed level of antibiotic resistance for bla'-BPTI [14-38]'-bla very well (periplasmic level compared to bla'-BPTI WT'-bla was 0.11 ± 0.05).

The β -lactamase system is also suitable to assess the effect of free cysteines on the *in vivo* stability of a protein

During heterologous protein expression in *E. coli*, the presence of unpaired cysteines in recombinant, disulfide bond containing proteins can promote the formation of incorrect intra- and intermolecular disulfide bonds, leaving the protein in inactive and aggregation-prone conformations (27). Elimination of free cysteines *via* site-directed mutagenesis has successfully been used to increase the stability, specific activity, and expression of these proteins and reduce their aggregation propensity (14, 30). However, since the




FIG. 6. Steady-state protein levels of different bla'-BPTI-bla variants *in vivo* correlate well with the corresponding levels of antibiotic resistance. The relative steady-state protein levels in whole cell extracts were detected by Western blot using an anti- β -lactamase antibody. Band intensities of β -lactamase (circle) or tripartite fusions containing different BPTI variants (filled diamonds) were normalized to the protein levels of cells expressing bla'-BPTI WT'-bla (open circle). In the case of bla'-BPTI [14-38]'-bla, the protein level was determined in whole cell extracts (open diamond) and in soluble, periplasmic fractions (triangle). In both cases, the protein level was adjusted to the protein level of bla'-BPTI WT'-bla in whole cell extracts or the soluble, periplasmic cell fraction, respectively. The trend line includes the value for the soluble periplasmic fraction of bla'-BPTI [14-38]'-bla and excludes the value for the whole cell extract of bla'-BPTI [14-38]'-bla. Data are expressed as mean values $\pm$ SD.

substitution of cysteines has also been shown to decrease protein stability by reducing hydrophobic interactions or generating cavities in the protein core (30), the effect of such mutations is hard to predict and can largely depend on the amino acid the cysteine is replaced with (21).

WT human granulocyte-colony stimulating factor (hG-CSF), which forms two natural disulfide bonds and contains one unpaired cysteine (Cys17), has a high propensity to aggregate, even under native-like conditions (35). This aggregation propensity is significantly decreased when the free cysteine is eliminated (35). In agreement with this observation, introduction of hG-CSF C17S into the β -lactamase system leads to an substantial increase in antibiotic resistance over a range of PenV concentrations compared to WT hG-CSF (Fig. 7) (13). This suggests that the β -lactamase technique can be used to identify cysteine mutations that are beneficial for the expression and *in vivo* stability of the corresponding protein by randomly mutating the proteins cysteines and simply selecting for increased levels of antibiotic resistance.

Discussion

Elimination or destabilization of the Cys14-Cys38 disulfide of BPTI leads to an increased expression in the bacterial periplasm

Despite the increasing number of studies investigating the folding and stability of proteins in the living cell (20), the fundamental question as to what extent *in vitro* folding experiments reflect the actual folding pathway *in vivo* has not been sufficiently answered for many proteins. In this study, we chose a multi-disulfide-bonded protein that is particularly poorly expressed in heterologous systems with the aim of selecting for variants that show improved folding and ex-




FIG. 7. Substitution of Cys17 in hG-CSF with serine leads to an increase in antibiotic resistance as part of the β -lactamase system. WT hG-CSF, which contains two disulfide bonds (Cys36-Cys42 and Cys64-Cys74) and one unpaired cysteine (Cys17), is prone to aggregation, even under native-like conditions (35). Substitution of the free cysteine with serine significantly decreases the proteins propensity to aggregate (35). Mid-log phase cells of *E. coli* MG1655 Δ ampC expressing bla'-hG-CSF WT'-bla or bla'-hG-CSF C17S'-bla, respectively, were normalized to OD_{600 nm} = 1. Serial dilutions of cultures from 10⁰ to 10⁻⁵ were spotted on LB plates containing different concentrations of ampicillin. After 18 h of incubation at 37°C, growth or no growth for each dilution for each ampicillin concentration was determined.

pression in the periplasmic space of *E. coli*. The test protein BPTI and many of its mutants have already been extensively characterized *in vitro*, allowing a direct comparison of mutants described in the literature with variants obtained in our *in vivo* selection.

Both genetic selection systems employed in this study were designed to exclusively identify variants that are successfully exported to the oxidizing environment of the periplasm, ensuring that we isolated BPTI variants showing increased protein levels in the bacterial compartment that would favor the correct formation of the protein's disulfide bonds. Strikingly, BPTI variants that resulted in the strongest phenotypes indicative of improved folding and expression in both selection systems completely eliminated one of BPTI's three native disulfide bonds, Cys14-Cys38. When analyzing our isolated BPTI variants in which no cysteines were mutated, we further noticed a high degree of overlap with BPTI variants sensitive to the reducing agent dithiothreitol (DTT) that were previously isolated in a screen by Coplen (2). This screen identified BPTI variants that are able to fold into an active conformation but, unlike WT BPTI, rapidly lose their protease inhibitory activity upon addition of DTT and are consequently inactivated in the presence of trypsin (2, 18). In total, our selections for increased folding and expression of BPTI in the bacterial periplasm yielded 8 variants (G12D, A16T, Y35N, Y35G, F33L, G28W, P13S, and G36D) that are known to be DTT-sensitive as single amino acid substitutions *in vitro* and/or were shown reduce the effective concentration of the Cys14-Cys38 disulfide, increase the rate constant for its reduction, and reduce its stability *in vitro* by up to 21 kJ/mol (BPTI Y35G) (2, 17). Five of the DTT-sensitive mutants (G12D, A16T, Y35N, Y35G, and F33L) have further been shown to selectively make the Cys14-Cys38 disulfide susceptible to reduction by DTT (17). For these variants, it was suggested that the resulting loss of BPTI activity was due to an increased flexibility of the BPTI variants and that the mutations might

favor the intramolecular rearrangement of intermediates (2, 17, 18). Altogether, 65% of the BPTI variants obtained in the *in vivo* phage selection contain amino acid substitutions that either destabilize or eliminate the Cys14-Cys38 disulfide bond *in vitro*. This is a remarkable overlap, considering that there are 1102 single amino acid substitutions possible for the BPTI sequence. The idea that destabilization or removal of Cys14-Cys38 is key to improving the folding of BPTI in the bacterial periplasm is further supported by our findings that the level of antibiotic resistance in the β -lactamase system measured *in vivo* directly correlates with the extent of thermodynamic destabilization of the Cys14-Cys38 disulfide caused by a given single point mutation *in vitro* (Fig. 3) and that the relative protein level of BPTI C14S C38S expressed on its own is significantly enhanced compared to WT BPTI.

Elimination of the Cys14-Cys38 disulfide might prevent its unfavorable, early formation of in vivo

That mutations reducing a protein's *in vitro* stability lead to an increase in expression *in vivo* might appear counterintuitive. However, the formation of Cys14-Cys38 is particularly problematic in BPTI's *in vitro* folding pathway due to its early but nonproductive formation in BPTI folding and its involvement in the rate-limiting step of the overall BPTI folding




FIG. 8. Consensus folding pathway of WT BPTI *in vitro*, modified from Creighton and Goldenberg (7) and Weissman and Kim (8, 45, 46). Starting from fully reduced BPTI (far left), the [14-38] intermediate is formed much more rapidly than any other species containing one disulfide-bond (9). However, the vast majority of [14-38] molecules are either reduced or isomerized before they form the thermodynamically more stable intermediates [30-51] or [5-55] (1). The most productive folding pathway for BPTI proceeding from the single disulfide-bonded species occurs *via* the two intermediates [5-14; 30-51] and [5-38; 30-51], which are in rapid equilibrium with each other and contain non-native disulfides (5, 10). At neutral pH, a large fraction of the BPTI molecules accumulates as kinetic traps (N' and N*), which only slowly isomerize toward the very native-like species (45, 46). Once NH₃SH is formed, the Cys14-Cys38 disulfide is introduced rapidly to obtain native BPTI (4). Note that the relative distribution of the double disulfide-bonded species is dependent on the pH (10, 45). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com/ars).

reaction (Fig. 8) (6, 46, 49). Due to the high reactivity of Cys14 and Cys38 and the significant conformational preference for introducing the Cys14-Cys38 disulfide during BPTI refolding *in vitro* at neutral pH, the [14-38] intermediate is formed much more rapidly from reduced BPTI than any other species containing a single disulfide bond, native or non-native (1, 8, 9). Despite this, [14-38] is not a very productive folding intermediate. The vast majority of [14-38] molecules are either reduced or isomerized before they accumulate in the form of the more stable single disulfide-bonded species [5-55] and [30-51] *in vitro* (41, 45, 46). However, the reduction or isomerization of the Cys14-Cys38 disulfide that would allow for this efficient folding pathway might be more difficult in the very oxidizing environment of the periplasm (38) than in *in vitro* refolding reactions, which tend to be done under less oxidizing conditions. Importantly, in the absence of other stabilizing effects such as an additional disulfide bond, the sole formation of Cys14-Cys38 in reduced BPTI does not substantially stabilize the native conformation *in vitro* (12). In *E. coli*, BPTI [14-38] does not appear to adopt a soluble, stable conformation, as reflected by its low MIC and its accumulation in the insoluble fraction in the β -lactamase system. Therefore, the early and rapid formation of Cys14-Cys38 in the periplasm might favor the accumulation of BPTI in an aggregation prone state, reducing the number of molecules that can proceed folding toward [5-55] and [30-51], which are thermodynamically more stable *in vitro* (1). Consistently, BPTI variants that mimic single disulfide-bonded intermediates [5-55] and [30-51] *in vivo* as reflected by their increased MICs in the β -lactamase system. In fact, the stabilities of BPTI's native disulfide bonds as determined *in vitro* correlate well with the observed antibiotic resistance of the corresponding tripartite fusions *in vivo*, suggesting that the β -lactamase system is well suited to assess the stabilities of different BPTI variants in the living cell.

Elimination of the Cys14-Cys38 disulfide might further prevent the accumulation of protease-sensitive intermediates in later stages of BPTI folding

Preventing or decreasing the rapid formation of Cys14-Cys38 in the early folding of BPTI *in vivo* might be sufficient to explain the superior phenotypes of our selected BPTI variants that eliminated or destabilized this disulfide. However, formation and subsequent reduction of Cys14-Cys38 is also critical in later folding stages *in vitro*, which might also help explain the enhanced antibiotic resistance of tripartite fusions in which both Cys14 and Cys38 are replaced. At neutral pH, a large fraction of BPTI molecules accumulates in the form of the kinetic traps [5-55; 14-38] (N*) or [14-38; 30-51] (N') (7, 46). For folding to proceed, N* and N' must reduce Cys14-Cys38 and unfold substantially to isomerize into the native-like NH₃SH [5-55; 30-51] (46). The reduction and isomerization of Cys14-Cys38 appears to be the rate-limiting step in the productive folding of BPTI *in vitro* at neutral pH (5, 7). Reduction and isomerization of Cys14-Cys38, however, might be especially problematic in the periplasm, which is high in oxidase but low in isomerase activity (19).

All the double disulfide-bonded intermediates N*, N', and NH₃SH show substantial native-like structure *in vitro* (39, 42). However, the amount of native structure in a BPTI intermediate and its lifetime under optimized conditions *in vitro* do

not necessarily indicate the proteolytic sensitivity of that species *in vivo*. Although the kinetic traps N' and N* persist for long periods of time under appropriate conditions *in vitro* (6, 46, 49), the majority of N' molecules are actually unfolded at physiological temperatures (7), suggesting that this species might be prone to proteolysis at 37°C *in vivo*. Of the three intermediates, NH_{SH}^{SH} is the most stable and native-like species (4, 44) and is known to fold into its active, native conformation both *in vitro* under physiological temperatures and when expressed in the periplasm of *E. coli* (28). Although its melting temperature is about 30°C lower than that of WT BPTI, it is still almost 40°C higher than the cultivation temperature of *E. coli*, suggesting that NH_{SH}^{SH} is relatively stable *in vivo* (44). In good agreement with these findings, the BPTI variant [5–55; 30–51] that represents the NH_{SH}^{SH} species leads to the highest MIC and protein level among the three double disulfide-bonded variants tested (Table 2). On the other hand, the two variants that imitate the kinetically trapped species N* and N' ([5–55; 14–38] and [14–38; 30–51], respectively) exhibit substantially lower *in vivo* stabilities, as reflected by decreased levels of antibiotic resistance and steady-state protein levels in the β -lactamase system, suggesting that they are proteolytically more sensitive *in vivo*.

Because antibiotic resistance is determined by the steady-state levels of soluble and periplasmic protein, it is possible that the low MIC values of N* and N' are caused in part by a problematic early formation of Cys14-Cys38, inducing protein aggregation. However, the very good correlation between antibiotic resistance and protein level in whole cell extracts for N*, N', and NH_{SH}^{SH} suggests that aggregation is not the dominating factor for the decreased MIC of N* and N' (Table 2). In contrast to [14–38], N* and N' both possess an additional, stabilizing disulfide bond, allowing the protein to reach other, more folded and less aggregation prone conformations. Remarkably, the phenotype conferred by bla'-BPTI WT-bla is intermediate (Fig. 4A). This may result from a mixed population in which some molecules populate the very stable, native state (leading to high levels of antibiotic resistance) and other molecules populate the kinetically trapped intermediate states N* or N' (leading to low levels of antibiotic resistance).

In addition to its impact on the early folding events of BPTI, the elimination or destabilization of Cys14-Cys38 might therefore also be associated with a simplification of BPTI's folding pathway *in vivo* in later folding stages, in which the accumulation of the proteolytically sensitive intermediates N* and N' is prevented or decreased. Variants that destabilize Cys14-Cys38 might favor the formation of double disulfide-bonded species with non-native disulfides, which are more likely to undergo intramolecular rearrangements and are part of the most productive folding route of BPTI *in vitro*, as it has been already shown for several of the BPTI variants isolated in our selection (F33L, Y23L, F4L, and Y35L) (50). This might lead to a preferred formation of the stable and very native-like species NH_{SH}^{SH}.

Interestingly, in variants of BPTI in which the formation of the Cys14-Cys38 disulfide bond was prevented, the rate of formation of native-like BPTI decreased from 9 s⁻¹ to 1.6 × 10⁻³ s⁻¹ at 25°C and pH 8.7 *in vitro* (15). However, this effect was diminished when experiments were performed at 37°C and at a less basic pH (8.3); under these conditions, only a 3-fold decrease in the overall folding rate for native BPTI

was observed (28). Our finding that BPTI C14S C38S shows increased protein levels compared to BPTI WT when expressed in the bacterial periplasm in absence of β -lactamase, an observation also made by (31), suggests that this slightly higher rate of formation of the native or native-like protein for BPTI WT compared to [5–55; 30–51] *in vitro* cannot, if even relevant *in vivo*, compensate for the potentially negative impact of the presence of Cys14-Cys38 in the early and later folding stages of BPTI *in vivo*.

The observation that the elimination of a stabilizing disulfide bond enhances the expression of BPTI might provoke the question why it was not eliminated by nature in the course of evolution. However, BPTI variants in which the Cys14-Cys38 disulfide is eliminated by substituting one or both of the involved cysteines are known to be cleaved by trypsin up to 10,000-fold more rapidly (47) and show decreased secretion efficiencies in yeast by up to 30% (24), suggesting that Cys14-Cys38 is important for the *in vivo* function and protease resistance of the protein.

Dependence of BPTI folding on the presence of folding factors

Our data suggest that the elimination or reduction of the kinetic traps N* and N' *in vivo* might increase the level of BPTI in the bacterial periplasm. In BPTI's natural environment, the endoplasmic reticulum, these species are likely to be isomerized by the eukaryotic disulfide bond isomerase (protein disulfide isomerase [PDI]), which has been shown to promote isomerization of these kinetic traps and enhance the formation of native BPTI by 27-fold *in vitro* (48). In fact, co-expression of rat PDI has been successfully used to increase the expression of BPTI in *E. coli* (32). Compared to its eukaryotic counterpart PDI, the isomerase activity of the bacterial enzyme responsible for disulfide bond isomerization in the periplasm, DsbC, is relatively low (37). Consistent with that, we did not find the level of antibiotic resistance conferred by various BPTI tripartite fusions to be strongly dependent on the presence of native levels of DsbC (data not shown). BPTI folding in *E. coli*, however, severely depends on the activity of the disulfide bond oxidase DsbA (33). The importance of DsbA for BPTI folding is supported by our finding that *dsbA*⁻ strains expressing different bla-BPTI fusions showed decreased levels of antibiotic resistance compared to a *dsbA*⁺ strain (data not shown).

Conclusion

Presumably due to the differences in the redox-environment of the endoplasmic reticulum and the bacterial periplasm, the heterologous expression of disulfide-rich, heterologous proteins in *E. coli* is often very challenging (32). Our results for BPTI and hG-CSF indicate that our tripartite fusion systems are well suited to enhance expression and folding of difficult to express heterologous proteins in the bacterial periplasm by random mutation of the target gene and a simple selection for improved phenotypes in our systems. The feasibility of our approach is supported by the good correlation between the relative level of antibiotic resistance and the relative level of the tripartite fusion in the β -lactamase system (Fig. 6) and the enhanced protein levels of selected BPTI variants compared to BPTI WT (determined for double mutant C14S C38S and single mutants K26M and G28W) in absence of β -lactamase

we observe. Further, the majority of variants selected for increased expression of BPTI eliminates or destabilizes the Cys14-Cys38 disulfide bond, suggesting that circumvention of Cys14-Cys38-related folding problems in early or later folding stages may improve the expression of BPTI *in vivo* and compensate for the apparent loss in stability *in vitro*. For proteins with unpaired cysteines like hG-CSF, our systems can be used to easily identify if and how free cysteines can be substituted to increase expression and *in vivo* stability of the protein. Our results therefore emphasize the power of genetic selection to identify and circumvent critical steps and residues problematic for in the *in vivo* folding pathway of proteins without the need to perform time-consuming site-directed mutagenesis experiments. Although we used an extremely well-studied model protein here, this technique should be applicable to a variety of target proteins with potentially unknown folding pathways. In cases where an unmutagenized target protein is preferred, our selection systems also provide the convenient possibility of fine-tuning the redox-environment of the periplasm for the enhanced expression of a target protein by mutating co-expressed folding factors such as oxidoreductases or proteins involved in redox-maintenance.

Acknowledgments

We thank George Georgiou for the generous gift of BPTI antibody. We are further grateful to F.X. Schmid and B. Eckert for providing us with fd phage.

Author Disclosure Statement

No competing financial interests exist.

References

- Bulaj G and Goldenberg DP. Early events in the disulfide-coupled folding of BPTI. *Protein Sci* 8: 1825–1842, 1999.
- Coplen LJ, Frieden RW, and Goldenberg DP. A genetic screen to identify variants of bovine pancreatic trypsin inhibitor with altered folding energetics. *Proteins* 7: 16–31, 1990.
- Cornelis P. Expressing genes in different *Escherichia coli* compartments. *Curr Opin Biotechnol* 11: 450–454, 2000.
- Creighton T. Disulphide-coupled protein folding pathways. *Philos Trans R Soc Lond B Biol Sci* 348: 5–10, 1995.
- Creighton TE. Conformational restrictions on the pathway of folding and unfolding of the pancreatic trypsin inhibitor. *J Mol Biol* 113: 275–293, 1977.
- Creighton TE. Protein folding pathways determined using disulphide bonds. *Bioessays* 14: 195–199, 1992.
- Creighton TE and Goldenberg DP. Kinetic role of a metastable native-like two-disulphide species in the folding transition of bovine pancreatic trypsin inhibitor. *J Mol Biol* 179: 497–526, 1984.
- Dadlez M and Kim PS. A third native one-disulphide intermediate in the folding of bovine pancreatic trypsin inhibitor. *Nat Struct Biol* 2: 674–679, 1995.
- Dadlez M and Kim PS. Rapid formation of the native 14–38 disulfide bond in the early stages of BPTI folding. *Biochemistry* 35: 16153–16164, 1996.
- Darby NJ, Morin PE, Talbo G, and Creighton TE. Refolding of bovine pancreatic trypsin inhibitor via non-native disulphide intermediates. *J Mol Biol* 249: 463–477, 1995.
- Darby NJ, van Mierlo CP, and Creighton TE. The 5–55 single-disulphide intermediate in folding of bovine pancreatic trypsin inhibitor. *FEBS Lett* 279: 61–64, 1991.
- Ferrer M, Barany G, and Woodward C. Partially folded, molten globule and molten coil states of bovine pancreatic trypsin inhibitor. *Nat Struct Biol* 2: 211–217, 1995.
- Foit L, Morgan GJ, Kern MJ, Steimer LR, von Hacht AA, Titchmarsh J, Warriner SL, Radford SE, and Bardwell JC. Optimizing protein stability *in vivo*. *Mol Cell* 36: 861–871, 2009.
- Fremaux I, Mazeres S, Brisson-Lougarre A, Arnaud M, Ladurantie C, and Fournier D. Improvement of *Drosophila* acetylcholinesterase stability by elimination of a free cysteine. *BMC Biochem* 3: 21, 2002.
- Goldenberg DP. Kinetic analysis of the folding and unfolding of a mutant form of bovine pancreatic trypsin inhibitor lacking the cysteine-14 and –38 thiols. *Biochemistry* 27: 2481–2489, 1988.
- Goldenberg DP. Native and non-native intermediates in the BPTI folding pathway. *Trends Biochem Sci* 17: 257–261, 1992.
- Goldenberg DP, Bekeart LS, Laheru DA, and Zhou JD. Probing the determinants of disulfide stability in native pancreatic trypsin inhibitor. *Biochemistry* 32: 2835–2844, 1993.
- Goldenberg DP, Berger JM, Laheru DA, Wooden S, and Zhang JX. Genetic dissection of pancreatic trypsin inhibitor. *Proc Natl Acad Sci USA* 89: 5083–5087, 1992.
- Hiniker A, Collet JF, and Bardwell JC. Copper stress causes an *in vivo* requirement for the *Escherichia coli* disulfide isomerase DsbC. *J Biol Chem* 280: 33785–33791, 2005.
- Ignatova Z. Monitoring protein stability *in vivo*. *Microb Cell Fact* 4: 23, 2005.
- Ishikawa M, Iijima H, Satake-Ishikawa R, Tsumura H, Iwamatsu A, Kadota T, Shimada Y, Fukamachi H, Kobayashi K, Matsuki S, *et al*. The substitution of cysteine 17 of recombinant human G-CSF with alanine greatly enhanced its stability. *Cell Struct Funct* 17: 61–65, 1992.
- Kibria FM and Lees WJ. Balancing conformational and oxidative kinetic traps during the folding of bovine pancreatic trypsin inhibitor (BPTI) with glutathione and glutathione disulfide. *J Am Chem Soc* 130: 796–797, 2008.
- Kirby AJ. Effective molarities for intramolecular reactions. *Adv Phys Org Chem* 17: 183–278, 1980.
- Kowalski JM, Parekh RN, and Wittrup KD. Secretion efficiency in *Saccharomyces cerevisiae* of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. *Biochemistry* 37: 1264–1273, 1998.
- Krebber C, Spada S, Desplancq D, Krebber A, Ge L, and Pluckthun A. Selectively-infective phage (SIP): a mechanistic dissection of a novel *in vivo* selection for protein-ligand interactions. *J Mol Biol* 268: 607–618, 1997.
- Krokoszynska I, Dadlez M, and Otlewski J. Structure of single-disulfide variants of bovine pancreatic trypsin inhibitor (BPTI) as probed by their binding to bovine beta-trypsin. *J Mol Biol* 275: 503–513, 1998.
- Leatherbarrow RJ and Fersht AR. Protein engineering. *Protein Eng* 1: 7–16, 1986.
- Marks CB, Naderi H, Kosen PA, Kuntz ID, and Anderson S. Mutants of bovine pancreatic trypsin inhibitor lacking cysteines 14 and 38 can fold properly. *Science* 235: 1370–1373, 1987.
- Martin A, Schmid FX, and Sieber V. Prosided: a phage-based method for selecting thermostable proteins. *Methods Mol Biol* 230: 57–70, 2003.

30. McRee DE, Redford SM, Getzoff ED, Lepock JR, Hallewell RA, and Tainer JA. Changes in crystallographic structure and thermostability of a Cu, Zn superoxide dismutase mutant resulting from the removal of a buried cysteine. *J Biol Chem* 265: 14234–14241, 1990.
31. Nilsson B, Berman-Marks C, Kuntz ID, and Anderson S. Secretion incompetence of bovine pancreatic trypsin inhibitor expressed in *Escherichia coli*. *J Biol Chem* 266: 2970–2977, 1991.
32. Ostermeier M, De Sutter K, and Georgiou G. Eukaryotic protein disulfide isomerase complements *Escherichia coli* dsbA mutants and increases the yield of a heterologous secreted protein with disulfide bonds. *J Biol Chem* 271: 10616–10622, 1996.
33. Ostermeier M and Georgiou G. The folding of bovine pancreatic trypsin inhibitor in the *Escherichia coli* periplasm. *J Biol Chem* 269: 21072–21077, 1994.
34. Raines RT. Ribonuclease A. *Chem Rev* 98: 1045–1066, 1998.
35. Raso SW, Abel J, Barnes JM, Maloney KM, Pipes G, Treuheit MJ, King J, and Brems DN. Aggregation of granulocyte-colony stimulating factor *in vitro* involves a conformationally altered monomeric state. *Protein Sci* 14: 2246–2257, 2005.
36. Schwarz H, Hinz HJ, Mehlich A, Tschesche H, and Wenzel HR. Stability studies on derivatives of the bovine pancreatic trypsin inhibitor. *Biochemistry* 26: 3544–3551, 1987.
37. Segatori L, Paukstelis PJ, Gilbert HF, and Georgiou G. Engineered DsbC chimeras catalyze both protein oxidation and disulfide-bond isomerization in *Escherichia coli*: reconciling two competing pathways. *Proc Natl Acad Sci USA* 101: 10018–10023, 2004.
38. Sevier CS and Kaiser CA. Formation and transfer of disulphide bonds in living cells. *Nat Rev Mol Cell Biol* 3: 836–847, 2002.
39. Stassinopoulou CI, Wagner G, and Wuthrich K. Two-dimensional ¹H NMR of two chemically modified analogs of the basic pancreatic trypsin inhibitor. Sequence-specific resonance assignments and sequence location of conformation changes relative to the native protein. *Eur J Biochem* 145: 423–430, 1984.
40. Swartz JR. Advances in *Escherichia coli* production of therapeutic proteins. *Curr Opin Biotechnol* 12: 195–201, 2001.
41. van Mierlo CP, Darby NJ, Keeler J, Neuhaus D, and Creighton TE. Partially folded conformation of the (30–51) intermediate in the disulphide folding pathway of bovine pancreatic trypsin inhibitor. ¹H and ¹⁵N resonance assignments and determination of backbone dynamics from ¹⁵N relaxation measurements. *J Mol Biol* 229: 1125–1146, 1993.
42. van Mierlo CP, Darby NJ, Neuhaus D, and Creighton TE. (14–38, 30–51) double-disulphide intermediate in folding of bovine pancreatic trypsin inhibitor: a two-dimensional ¹H nuclear magnetic resonance study. *J Mol Biol* 222: 353–371, 1991.
43. van Mierlo CP, Darby NJ, Neuhaus D, and Creighton TE. Two-dimensional ¹H nuclear magnetic resonance study of the (5–55) single-disulphide folding intermediate of bovine pancreatic trypsin inhibitor. *J Mol Biol* 222: 373–390, 1991.
44. Wagner G, Kalb AJ, and Wuthrich K. Conformational studies by ¹H nuclear magnetic resonance of the basic pancreatic trypsin inhibitor after reduction of the disulfide bond between Cys-14 and Cys-38. Influence of charged protecting groups on the stability of the protein. *Eur J Biochem* 95: 249–253, 1979.
45. Weissman JS and Kim PS. A kinetic explanation for the rearrangement pathway of BPTI folding. *Nat Struct Biol* 2: 1123–1130, 1995.
46. Weissman JS and Kim PS. Reexamination of the folding of BPTI: predominance of native intermediates. *Science* 253: 1386–1393, 1991.
47. Zakharova E, Horvath MP, and Goldenberg DP. Functional and structural roles of the Cys14-Cys38 disulfide of bovine pancreatic trypsin inhibitor. *J Mol Biol* 382: 998–1013, 2008.
48. Zapun A and Creighton TE. Effects of DsbA on the disulfide folding of bovine pancreatic trypsin inhibitor and alpha-lactalbumin. *Biochemistry* 33: 5202–5211, 1994.
49. Zhang JX and Goldenberg DP. Amino acid replacement that eliminates kinetic traps in the folding pathway of pancreatic trypsin inhibitor. *Biochemistry* 32: 14075–14081, 1993.
50. Zhang JX and Goldenberg DP. Mutational analysis of the BPTI folding pathway: I. Effects of aromatic—>leucine substitutions on the distribution of folding intermediates. *Protein Sci* 6: 1549–1562, 1997.

Address correspondence to:

Dr. James C.A. Bardwell

Department of Molecular, Cellular and Developmental Biology

Howard Hughes Medical Institute

University of Michigan

Ann Arbor, MI 48109

E-mail: jbardwel@umich.edu

Date of first submission to ARS Central, October 18, 2010; date of final revised submission, November 28, 2010; date of acceptance, November 28, 2010.

Abbreviations Used

BPTI = bovine pancreatic trypsin inhibitor

DTT = dithiothreitol

hG-CSF = human granulocyte-colony stimulating factor

LB = lysogeny broth, also known as

Luria-Bertani broth

MIC = minimal inhibitory concentration

PCR = polymerase chain reaction

PDI = protein disulfide isomerase

pfu = plaque forming unit

PROSIDE = protein stability increased by directed evolution

SD = standard deviation

WT = wild-type

This article has been cited by:

1. Gustavo Salinas, Leonardo Pellizza, Mariana Margenat, Martín Fló, Cecilia Fernández. 2011. Tuned Escherichia coli as a host for the expression of disulfide-rich proteins. *Biotechnology Journal* **6**:6, 686-699. [[CrossRef](#)]